STUDY OF PEMBROLIZUMAB IN METASTATIC BILIARY TRACT CANCER AS SECOND-LINE TREATMENT AFTER FAILING TO AT LEAST ONE CYTOTOXIC CHEMOTHERAPY REGIMEN: INTEGRATION OF GENOMIC ANALYSIS TO IDENTIFY PREDICTIVE MOLECULAR SUBTYPES: